Drugs / Commercial Anti-CD19 CAR-T Cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07622784 Background | Jun 2026 → Jun 2028 expected | B-cell non-Hodgkin lymphoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Commercial Anti-CD19 CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07622784 ↗ |
| Modality | Cell therapy | “commercial anti-CD19 CAR-T cell infusion” NCT07622784 ↗ |